Journal of Pharmacology, Genetics and Molecular Biology (JPGMB)
ISSN: 3049-3757 | Vol. 01, Issue-04, July-Aug, 2025

Pharmacological Modulation of Gut Microbiota in Metabolic Syndrome

Shubham Kumar Maurya[1*], Jai Shankar Pandey[1], Adarsh Mishra[1], Arpana Prajapati[1], Rohit Kumar Srivastava[1]

[1]Faculty of Nursing and Paramedical, Mahayogi Gorakhnath University, Gorakhpur, U.P., Pin: 273007

***Corresponding Author E-mail: shubhamkumarmaurya@outlook.com**

ABSTRACT

Gut microbiota has been identified as a regulator of metabolic health, especially the metabolism syndrome (MetS), which is a multifactorial disease, including obesity, insulin resistance, dyslipidemia, and hypertension. Recent preclinical models involving rodents exposed to high-fat diets have demonstrated therapeutic benefits of pharmacological agents (e.g. metformin, berberine, and probiotics, prebiotics, and bile acid modulators, to mention a few) not only on direct molecular targets but also on the gut microbiome. These agents Walter U. [2016] Enhance the abundance of probiotic microbial taxa such as *Akkermansia muciniphila* and Bifidobacterium, Short chain fatty acid (SCFA) production, and improve gut barrier integrity as well as attenuate systemic inflammation and metabolic endotoxemia. The review is critical in assessing the methods, results, and actions taken by these interventions to improve host-microbiota interactions in the alleviation of MetS characteristics, such as raised insulin sensitivity, glucose, and lipid metabolism. It is also discussing some critical drawbacks of existing preclinical models, including species-level disparities in microbiota and the brevity of observation, which could be problematic to translate to clinical settings. It gives prominence on the implications on microbiota-modulating treatments, integrations of microbiome-modulating adjuncts, and how this can be studied further, such as long-term studies and individual approaches to treatment. On balance, it is possible to talk about pharmacological modulation of the microbiome of the gut as the new promising way of improving treatment outcomes of MetS and its sustainability.

Key Words:

Gut Microbiota, Metabolic Syndrome, Metformin, Berberine, SCFAS, Dysbiosis, Bile Acid Modulators, Preclinical Studies

Article History:

Received on Feb 18, 2025

Revised on March 17, 2025

Accepted on July 29, 2025

Published on Aug 3, 2025

DOI: https://doi.org/10.64062/JPGMB.Vol1.Issue4.15

1. INTRODUCTION

The gut microbiota has within the last 10 years come to forefront as a major controlling mediator of host metabolic homeostasis, governing energy harvest, glucose metabolism, lipid storage and immune response. Metabolic Syndrome (MetS) is a complex syndrome of multiple symptoms that comprises central obesity, insulin resistance, hyperglycemia, dyslipidemia and hypertension. However, dysbiosis of gut microbiome is becoming associated with MetS.

Experimental feeding studies in animals proved that the excess of any food, especially fats and sugars, triggers the imbalance of the microbiome defined by low microbial diversity, high Firmicutes-to-Bacteroidetes ratios, and endotoxemia[1]. These changes lead to chronic low-grade inflammations in the body, insulin resistance signaling, as well as other characteristics of MetS. At the same time, some of the pharmacological compounds long applied to address metabolic imbalances have proved capable of altering microbiota of the gut, not only as secondary effects but an essential part of their modus operandi. The two way interaction between the ecology of microbes and the metabolism of the host provides an exciting border land in describing the mode of drug action and control of metabolism[2].



Figure 1: Dietary Fiber Fermentation and SCFA Production in Animal Gut Microbiota[3]

The use of rodent models has been especially useful in decoding these interactions, as simpler environments allow testing of the effects of pharmacological treatments on microbial composition and functionality. Metformin, berberine, and GLP-1 receptor agonists as well as other drugs have been shown to have microbiota-modulating effects in high-fat diet-obese mice, an effect appearing to improve metabolic parameters[4]. Through microbial changes, metabolic production, gut barrier (intestinal permeability), and inflammatory markers, scientists are finding ways through which the gut microbial behaviours are linked to systemic metabolic changes. This microbiome-focused view changes the traditional paradigm of action of drugs, positing that it is possible that not only by directly interacting with molecular targets can pharmacological effects be observed but also with the help of the microbiome. Insights open the door to microbiota-directed therapies and complementary therapies of MetS therapeutics[5].

1.1. Background Information and Context

Metabolic Syndrome is a disease burden that is escalating internationally and which is linked to the increased risk of type 2 diabetes, cardiovascular diseases, and the non-alcoholic fatty liver disease. The syndrome is traditionally discussed in the context of endocrinology and nutrition, but existing considerable evidence claims that it is strongly affected by the gut

microbiota an active ecosystem regularly interacting with diet constituents, immune response, and metabolism patterns. Previous studies on animal models demonstrated the role of intestinal dysbiosis in MetS pathogenesis through an endotoxemic state, persistent inflammation, changes in lipids and glucose metabolic pathways[6]. Due to the ongoing development of pharmacological approaches to the treatment of MetS, the focus has shifted to the role of these agents in the composition and an impact on the composition of the gut microbiome.

1.2. Objectives of the Review

This review aims to explore key aspects of pharmacological modulation of gut microbiota in metabolic syndrome, with the following objectives:

- To assess how drugs like metformin and berberine affect gut microbiota in MetS animal models.
- To examine how microbiota changes improve metabolic outcomes (e.g., insulin sensitivity, lipid levels).
- To explore mechanisms such as SCFA production, bile acid metabolism, and gut barrier repair.
- To review preclinical study methods used to analyze drug-microbiota interactions.
- To highlight research strengths, limitations, and future directions for microbiota-based MetS therapies.

1.3. Importance of the Topic

The knowledge of pharmacological influence on gut microbiota is important in the context of increased worldwide MetS prevalence and inadequate long-term effectiveness of treatment approaches that are currently used[7]. The gut microbiome is one of the variables that are alterable and capable of influencing either the positive or negative impact on drugs. Because studying interaction in live controlled animal models, the researchers will find mechanisms that are not evident in the animal studies; this is however subject to the confounding factors. Such understanding is of great importance to the future design of microbiota-therapeutics, personalized medicines, and more competent pharmacological treatment designed to turn around or counteract MetS pathophysiology. Furthermore, it leads to the introduction of the adjunct treatment, i.e., prebiotics, probiotics, or synbiotics that can be used synergistically with current drugs with improved clinical manifestations[8].

2. PRECLINICAL STUDIES AND METHODOLOGIES IN GUT MICROBIOTA MODULATION

The past decades of preclinical research has advanced the evidence of the potential of pharmacological agents to alter the microbiota within the gastrointestinal tract and shift metabolic results in metabolic syndrome (MetS), and most notably in rodent models of high-fat diet. Some of these interventions, such as antidiabetic medications, such as metformin, as well as natural products, such as berberine and probiotics, have demonstrated the capacity to improve insulin sensitivity, decrease body weight, and alleviate lipid and glucose metabolism,

which is commonly associated with beneficial alterations in the microbiome[9]. These changes can be captured by advanced methodologies like 16S rRNA sequencing and metagenomics whilst glucose tolerance tests in addition to lipid profiling and histological analyses are used to assess metabolic results. The advantage of such works is that they have controlled conditions and mechanical understanding of how they work in order to be able to recreate and study precise interactions between the host and the microbiota. Nevertheless, the findings can be directly applied to clinical practice because the limitations, which include species-specific microbiota, differences in metabolic physiology between rodents and animals, and brief study duration, will render this difficult. Therefore, in as much as they provide useful evidence, these studies need to be complemented by long-term, animal oriented studies to enhance their generalization[10].

2.1.Summary of Key Research Studies

Numerous studies still available in preclinical research findings stimulate the role of pharmacological drugs in regulating gut microbiota to improve metabolic syndrome (MetS) outcomes. All these studies have provided evidence that when intervention deriving at the gut microbiota is used, critical changes in metabolic parameters can be achieved. Pharmacological treatment with, especially, antidiabetic agents (metformin, etc.), plant extracts (berberine, etc.), and probiotics in animal models (especially rodents) has led to body weight loss, improved insulin sensitivity, improvements in glucose tolerance, and positive alterations in blood lipid metabolism[11]. All this is commonly attributed to compositional and functional changes in the gastrointestinal microbiota such as the elevated abundance of positive microbiota and the reduction of pro-inflammatory microbes.

2.2.Methodologies and Findings

The most commonly used methodological strategy is the induction of MetS in rodents by means of adopting high-fat diet (HFD) feeding schedules that mimic the essential aspects of animal metabolic disbalance. After the use of pharmacological intervention, gut microbial changes are measured with the help of powerful molecular tools, including 16S rRNA gene sequencing and whole-genome metagenome analysis, to read the taxonomic and functional changes of gut microbiota. Simultaneously, the metabolic levels are assessed by oral glucose tolerance tests (OGTT), insulin tolerance tests (ITT), fasting glucose test, fasting insulin tests, profiles of lipid concentrations, as well as liver and adipose tissues histopathology. Conclusions are always the same: pharmacological agents not only positively affect host metabolic but also normalize the microbiome, making it diverse and facilitating an increase of beneficial microbial genera such as Akkermansia, Bifidobacterium, and Lactobacillus. Such microbial changes are frequently associated with greater short-chain fatty acids (SCFAs), improved gut barrier and fewer systemic inflammations[12].

2.3.Critical Evaluation

- **Strengths**

The first major strength of the existing body of preclinical research is the fact that this body of research is able to characterize causal relationships between microbiota-mediated metabolic

benefits and pharmacological interventions[13]. The rodent models, especially with the model induced by high-fat diet, offer synthetic conditions in which one can control the variable with enough exactness and obtain reproducible results. These models have the capability of in-depth mechanistic analysis, such as monitoring microbial changes, quantifying systemic biomarkers, and making histological analysis. Also, more sophisticated methods like 16S rRNA sequencing, as well as metagenomics, provide a high-resolution view of the microbial composition and functional potential. Strength and reliability of these experimental methods can be further boosted by the reproducibility of the results in various studies e.g. improved insulin sensitivity, decrease of inflammation, as well as augmentation of the microbial diversity.

- **Weaknesses**

These studies have their limitations, in spite of being useful. Of particular concern is species specificity of gut microbiota; rodent microbiomes are far removed from those of other animals, another hindrance to direct translational relevance of findings. Besides, metabolic physiology of rodents does not necessarily replicate animal responses particularly where complex entities such as MetS are involved[14]. The high-fat diets that are used to artificially induce disease are beneficial but perhaps do not best represent the multifactorial aspects of MetS in animals. Also the study periods are short and no long-term follow-ups which hinders knowledge of sustainability and safety of pharmacological interventions. These shortcomings reflect on the necessity to be cautious about translating the preclinical findings into animal clinical practice and the relevance of complementary studies in animals.

3. PHARMACOLOGICAL AGENTS TARGETING GUT MICROBIOTA IN METABOLIC SYNDROME

Pharmacological interventions with metformin and berberine have demonstrated the potential benefit in animal models of metabolic syndrome (MetS) on gut microbiota using a high-fat diet[15]. Metformin in addition to enhancing glucose control enriches the beneficial microbes such as Akkermansia muciniphila and decreases pro-inflammatory bacteria, improves insulin sensitivity and gut barrier integrity. Berberine is a natural alkaloid, which restructures the gut microbiota by enlarging the SCFA-producing bacteria, involvement of Butyricicoccus and Roseburia, lowering the endotoxin, and activation of AMPK pathways, which lead to improved metabolic regulation[16].

Moreover, probiotics and prebiotics serve as adjuncts that balance the microbial wealth back to normally, increase the generation of SFCA, and reduce the components of systemic inflammation. Strains such as Lactobacillus and Bifidobacterium and fibers such as inulin augment metabolic markers and food intake controls through hormonal thermodynamics. Similarly the bile acid modulators have a secondary effect on the composition of the gut microbiota by changing the profiles of bile acids, stimulating beneficial taxa and the receptors such as FXR and TGR5. All these microbial and metabolic effects demonstrate why pharmacological treatment of the gut is an enticing solution to MetS[17].

3.1.Metformin and Gut Microbiota

Metformin, a first-line pharmacological agent of diabetes type 2, is gaining popularity of microbiota-modulating activity, besides its usual role in glycemic regulation. Metformin treatment during high-fat diet (HFD) generates rodents models related to metabolic syndrome (MetS) in which the abundance of the favorable microbial species, including Akkermansia muciniphila and Bacteroides, is substantially increased, whereas the levels of pro-inflammatory species, such as Desulfovibrio, are decreased[18]. These microbial changes are associated with enhanced systemic insulin sensitivity and glucose tolerance, reduced circulating inflammatory cytokines. Mechanistically, metformin changes the concentration of various bile acids, favoring the buildup of bile acids that suppressed pathogenic overgrowth and a healthy microbiota. In addition to this, it induces intestinal mucin production, which fortifies the gut wall and aids the prevention of endotoxins leaking into the blood by translocation, thereby reducing metabolic endotoxemia and low-grade systemic inflammation. These interacting effects underspace the dual role of metformin on the host metabolism and the gut ecosystem[19].

3.2.Berberine and Microbial Remodeling

Berberine is an isoquinoline alkaloid produced by plants, with demonstrated antimicrobial activity and potential as an antidiabetic aid, in preclinical trials. In rodents fed with HFD, supplementation with berberine leads to the significant re-modeling in the microbiome with the decreased abundance of pathogenic microbes e.g. Enterobacteriaceae and an enhanced abundance of health-promoting SCFA-producers e.g. genus Butyricicoccus and Roseburia. Such changes are also associated with enhanced insulin sensitivity, lowered hepatic steatosis, and lowered adiposity[20]. The anti-inflammatory effects of Berberine are also promoted by alteration of the gut-liver axis, as demonstrated by a lower LPS in the blood, which implies better intestinal barrier integrity. Also, berberine is believed to stimulate AMP-activated protein kinase (AMPK), which is an important regulator of the energy homeostasis and further adds to the weight of its metabolic advantages through both host and microbe-based mechanisms.



Figure 2: Berberine and Microbial interplay[21]

3.3.Probiotics and Prebiotics as Adjunct Agents

As adjuncts of pharmacologically derived therapy, probiotics and prebiotics have shown synergetic potential in the context of recreating intestinal microbial homeostasis in MetS

models. Probiotics bacteria like Lactobacillus rhamnosus and Bifidobacterium longum and prebiotic fibre like inulin and fructooligosaccharides (FOS) have been demonstrated to increase the level of SCFA, especially butyrate, enhancing colonic epithelial health and the sensitivity of insulin. These agents aid in restoring diversity among microbes, which is usually encroached in MetS. In rodent models, probiotic/prebiotic intervention has been shown to reduce pro-inflammatory cytokine levels (e.g., TNF- a, IL- 6), decrease or prevent weight gain, and beneficial effects on lipid profile[22]. Moreover, due to amplified appetite suppression hormone expression (e.g., GLP-1 and PYY) and better appetite control, it can be supposed that the agents normalize both the microbial and neuroendocrine axes of the energy balance process.

3.4.Bile Acid Modulators

Bile acid-based drugs are a new group of microbiota-directed drugs. These compounds (including bile acid sequestrants or farnesoid X receptor [FXR] antagonists) in rodent models result in modifications of the hormonal bile acid pool to more hydrophilic and less toxic species. The resulting altered patterns of bile acids promote the growth of the beneficial bacterial species like Bacteroides and Clostridium XIVa that transforms bile acids and produce SCFA. The change in the microbial ecosystem then stimulates the main metabolic receptors including FXR and Takeda G-protein receptor 5 (TGR5) that modify lipid and glucose metabolism, suppress inflammation and increase energy expenditure. Bile acid-based therapies provide dual mechanisms of beneficial modification to metabolism in MetS through the modulation of enterohepatic circulation and the microbiome simultaneously.

Table 1: Summary of Key Literature on Gut Microbiota and Metabolic Health[23]

Authors	Study	Focus Area	Methodology	Key Findings
Song et al. (2019)[24]	Inulin's effect on metabolic dysfunction in ob/ob mice	Prebiotic modulation of gut microbiota in MetS	Animal study on ob/ob mice; inulin supplementation; microbial and metabolic assessments	Inulin alleviated metabolic disorders by enriching beneficial microbes and partially restoring leptin pathways, improving glucose and lipid metabolism.
Tilg et al. (2020)[25]	Review of microbiota and metabolic inflammation	Gut microbiota and inflammation in MetS	Narrative literature review of microbiota–immune system interactions	Dysbiosis triggers low-grade systemic inflammation via LPS; microbiota modulation could reduce immune activation and improve metabolic health.

Wang et al. (2020a)[26]	Overview of gut microbiota's role in metabolic syndrome	Microbiota's role in metabolic dysfunction	Comprehensive review on microbiota–host metabolic interactions	Gut dysbiosis disrupts metabolism, bile acid signaling, and gut barrier function; restoring microbial balance may help manage MetS.
Wang et al. (2020b)[27]	Probiotics and FOS in gut-brain axis regulation in autism (with metabolic implications)	Indirect evidence of microbiota in metabolic health	Experimental intervention with probiotics and FOS; behavioral and metabolic outcome measures	Modulated gut microbiota reduced serotonergic overactivity and dopamine imbalance; findings support systemic benefits including potential metabolic improvements.

4. ROLE OF GUT MICROBIOTA IN THE PATHOGENESIS OF METABOLIC SYNDROME

The gut microbiota is a diverse and complex ecosystem, which is made up of trillions of microorganisms living in the gastrointestinal tract, it is imperative in the regulation of metabolic homeostasis in the host. An impairment of this microbial ecosystem (or dysbiosis) has been substantially linked to the evolution and development of metabolic syndrome (MetS), which is an amalgamation of several ailments such as obesity, insulin contrariness, dyslipidemia, and hypertension. The existence of gut microbes in healthy people leads to harvesting of energy, glucose and lipid metabolism regulation, and maintenance of intestinal barrier. But in MetS, microbial diversity is often lost, beneficial bacteria related to Akkermansia muciniphila and Bifidobacterium spp. are reduced, and the advantage of pro-inflammatory or endotoxin-producing bacteria such as Desulfovibrio is represented. This disproportion disrupts metabolic signal transduction, fueling systemic inflammation and changes in host immunity bringing into place a metabolic disorder.



Figure 3: Gut Microbiota Functions[28]

Short-chain fatty acids (SCFAs) especially acetate, propionate and butyrate production is one of the critical mechanisms between the association of gut microbiota and MetS pathogenesis. These SCFAs are generation products of microbial combination of dietary fibers, and provide the energy stores of colonocytes, glucose and lipid metabolic regulators, and inflammation modulators. Specifically, butyrate facilitates the integrity of intestinal epithelium, increases insulin sensitivity, and inhibits the inflammatory response. MetS patients associate a diminished SCFA synthesis with a dysfunctional gut barrier and an elevated systemic inflammation. This disruption of the gut lining has been termed colloquially as the leaky gut and, as a result, leads to translocation of pathogenic bacteria or their components such as lipopolysaccharides (LPS) into the systemic circulation leading to a state of low-grade inflammation that increases the risk of insulin resistance, hepatic steatosis, and cardiovascular disease.

The role of the gut microbiota is to regulate host metabolism by modulating bile acid metabolism and gut-derived hormones. Transformed bile acids are deconjugated by microbes and bind to receptors of the host, including farnesoid X receptor (FXR) and the G-protein-coupled bile acid receptor (TGR5). These receptors mediate glucose and lipid and energy homeostasis. The composition of the bile acid pool may be the shift towards dysbiosis, leading to the diminished signaling of these receptors and poor metabolic regulation. In analogous way, microbial metabolites also influence the release of satiety-sensitive hormones such as glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) that exert significant effects on controlling appetite, insulin secretion, and glucose tolerance. The changes in the microbial profile are thus able to affect the feeding behavior and energy storage to the extent of worsening the characteristics of MetS including obesity and insulin resistance[29].

5. DISCUSSION

Preclinical data point to the importance of pharmacological interventions in shaping of gut microbiota to alter characteristics of metabolic syndrome (MetS), whereby medications such as metformin and berberine elevated beneficial microbial taxa, short-chain fatty acid production, and intestinal barrier function. These effects of microbiota indicate that the efficacy of drugs can be partially dependent on microbial interactions providing new possibilities of microbiota-targeted treatment and individualized treatments. Nevertheless, the weaknesses of

its application, include species differences, short periods of the studies, and absence of long-term safety data, which also confirms the necessity of long-term and cross-species studies and mechanistic studies. Future research is to assess a combination of a pharmacological and microbiome-based treatment to maximize the decision of MetS management.

5.1.Interpretation of Findings

The synergistic effect of all the preclinical experiments seconded the major contribution of pharmacological agents to the remodeling of gut microbiome to address the characteristics of metabolic syndrome (MetS). Drugs like metformin, berberine and bile acid modulators do not only have a direct beneficial effect on metabolism but also change the microbial community in a manner that show systematic interactions increasing the host outcome. The improved glucose tolerance, lipid profiles, insulin sensitivity, and inflammation has a close connection with the microbial changes towards beneficial taxa such as Akkermansia muciniphila, Bifidobacterium, and SCFA genera producers. In addition, microbial reconstitution leads to enhanced SCFA formation and forced gut barrier and augmented endotoxemia as well as the stimulation of bile acids and satiety pathways. These results pose the possibility that intestinal microbiota has a decisive role in drug response in MetS and can contribute to the effectiveness of such interventions[30].

5.2.Implications and Significance

The new microbiome-based approach to pharmacotherapy is having far-reaching responses to the control of metabolic diseases. To begin with, it expands the mechanistic perspective on prescribed medicines by advocating that their activity can be mediated in part or in large important peripheral to the pathways associated with microbiota. Second, it also creates new directions in drug development, namely, the development of microbiota-specific or microbiota-improving pharmacological substances. Third, it promotes use of adjuncts with microbiota-modulating capabilities, i.e., probiotics, prebiotics, and synbiotics, to both supplement clinical outcomes when used in a treatment regimen. Moreover, microbiota profiling may find its use in personalized medicine where it would be possible to conduct customized interventions tailored to their microbial signatures. These implications are of special interest regarding the increasing global burden of MetS, where long-term efficacy and safety of already existing treatment are a matter of concern.

5.3.Gaps and Future Directions

Regardless of its compelling results, there exists a number of gaps that still need to be filled to make such lessons translatable more. A key obstacle is the use of rodent models, although informative in the mechanical specifics, considerably contrasting animals in matters of the microbiome constitution and metabolic activity. Such discrepancy constrains the direct translatability of results into the clinical practice. In addition, most preclinical studies are of short duration without data on maintenance and long-term safety of microbiota-modulating pharmacological interventions. The main areas of future research should be long-term studies, cross-species confirmation, mechanistic delineation of microbial-host interactions on molecular levels. The combinatory therapeutic approaches, which combine use of pharmacologic agents that would be in conjunction with microbiome-targeted strategies and interventions, like fecal microbiome transplantation or the use of genetically engineered

probiotics, need to be also investigated. Also, the discovery of certain microbial metabolites and signaling pathways which underlie therapeutic effect will be central to elaboration of precision-targeted treatment of MetS.

6. CONCLUSION

The ability to manipulate intestinal microbiota pharmacologically offers a promising model of metabolic syndrome (MetS) management, as one can observe in the increasing amount of preclinical studies with the use of high-fat diet-induced animal models. According to this review, widely adopted drugs, including metformin and berberine and adjunctive treatments, such as probiotics, prebiotics, and bile acid modulators, present considerable effects on the gut microbial composition and activity, potentially improving metabolic parameters, like inflammation, improved insulin-sensitivity, lipid profile, and glycemic control. These rewards have a close connection with higher prevalence of beneficial microbial taxa, heightened short-chain fatty acids (SCFA) production, enhanced intestinal barrier integrity and regulation of bile acids and hormonal signaling pathways. This evidence indicates that the intestinal microbiome does not always play an inert role but is an active participant in drug performance, and the designs of microbiota-focused changes in pharmacology are now available. Nonetheless, these results can be applied in clinical practice, it is necessary to address various limitations, such as interspecies microbiota variation, brief length of shown studies, and a lack of cumulative safety outcomes. The next step of the research would be mechanistic, long-term, and combinatory studies that would combine microbiome-specific and traditional treatment. In a final analysis, the manipulation of the gut microbiota is a prospective and fresh action to add to the current pharmacological treatments of MetS that could be used to enhance therapeutic outcome, and the way to personalization and more efficient treatment.

REFERENCES

1. Agus, A., Clément, K., & Sokol, H. (2021). Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut, 70(6), 1174-1182.
2. Aron-Wisnewsky, J., Vigliotti, C., Witjes, J., Le, P., Holleboom, A. G., Verheij, J., ... & Clément, K. (2020). Gut microbiota and animal NAFLD: disentangling microbial signatures from metabolic disorders. Nature reviews Gastroenterology & hepatology, 17(5), 279-297.
3. Cai, J., Rimal, B., Jiang, C., Chiang, J. Y., & Patterson, A. D. (2022). Bile acid metabolism and signaling, the microbiota, and metabolic disease. Pharmacology & Therapeutics, 237, 108238.
4. Chakaroun, R. M., Massier, L., & Kovacs, P. (2020). Gut microbiome, intestinal permeability, and tissue bacteria in metabolic disease: perpetrators or bystanders?. Nutrients, 12(4), 1082.
5. Chaplin, A., Carpéné, C., & Mercader, J. (2018). Resveratrol, metabolic syndrome, and gut microbiota. Nutrients, 10(11), 1651.
6. Cortés-Martín, A., Iglesias-Aguirre, C. E., Meoro, A., Selma, M. V., & Espín, J. C. (2021). Pharmacological therapy determines the gut microbiota modulation by a pomegranate extract nutraceutical in metabolic syndrome: a randomized clinical trial. Molecular Nutrition & Food Research, 65(6), 2001048.

7. Cronin, P., Joyce, S. A., O'Toole, P. W., & O'Connor, E. M. (2021). Dietary fibre modulates the gut microbiota. Nutrients, 13(5), 1655.
8. Crudele, L., Gadaleta, R. M., Cariello, M., & Moschetta, A. (2023). Gut microbiota in the pathogenesis and therapeutic approaches of diabetes. EBioMedicine, 97.
9. Dabke, K., Hendrick, G., & Devkota, S. (2019). The gut microbiome and metabolic syndrome. The Journal of clinical investigation, 129(10), 4050-4057.
10. Đanić, M., Stanimirov, B., Pavlović, N., Goločorbin-Kon, S., Al-Salami, H., Stankov, K., & Mikov, M. (2018). Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndrome. Frontiers in pharmacology, 9, 1382.
11. Di Marzo, V., & Silvestri, C. (2019). Lifestyle and metabolic syndrome: contribution of the endocannabinoidome. Nutrients, 11(8), 1956.
12. Gao, F., Lv, Y. W., Long, J., Chen, J. M., He, J. M., Ruan, X. Z., & Zhu, H. B. (2019). Butyrate improves the metabolic disorder and gut microbiome dysbiosis in mice induced by a high-fat diet. Frontiers in pharmacology, 10, 1040.
13. Guevara-Cruz, M., Flores-López, A. G., Aguilar-López, M., Sánchez-Tapia, M., Medina-Vera, I., Díaz, D., ... & Torres, N. (2019). Improvement of lipoprotein profile and metabolic endotoxemia by a lifestyle intervention that modifies the gut microbiota in subjects with metabolic syndrome. Journal of the American Heart Association, 8(17), e012401.
14. Guo, W. L., Pan, Y. Y., Li, L., Li, T. T., Liu, B., & Lv, X. C. (2018). Ethanol extract of Ganoderma lucidum ameliorates lipid metabolic disorders and modulates the gut microbiota composition in high-fat diet fed rats. Food & Function, 9(6), 3419-3431.
15. Kang, Y., Kang, X., Yang, H., Liu, H., Yang, X., Liu, Q., ... & Fan, W. (2022). Lactobacillus acidophilus ameliorates obesity in mice through modulation of gut microbiota dysbiosis and intestinal permeability. Pharmacological research, 175, 106020.
16. Kasprzak-Drozd, K., Oniszczuk, T., Stasiak, M., & Oniszczuk, A. (2021). Beneficial effects of phenolic compounds on gut microbiota and metabolic syndrome. International journal of molecular sciences, 22(7), 3715.
17. Li, L., Guo, W. L., Zhang, W., Xu, J. X., Qian, M., Bai, W. D., ... & Lv, X. C. (2019). Grifola frondosa polysaccharides ameliorate lipid metabolic disorders and gut microbiota dysbiosis in high-fat diet fed rats. Food & Function, 10(5), 2560-2572.
18. Li, T. T., Tong, A. J., Liu, Y. Y., Huang, Z. R., Wan, X. Z., Pan, Y. Y., ... & Zhao, C. (2019). Polyunsaturated fatty acids from microalgae Spirulina platensis modulates lipid metabolism disorders and gut microbiota in high-fat diet rats. Food and chemical toxicology, 131, 110558.
19. Liu, J., Yue, S., Yang, Z., Feng, W., Meng, X., Wang, A., ... & Yan, D. (2018). Oral hydroxysafflor yellow A reduces obesity in mice by modulating the gut microbiota and serum metabolism. Pharmacological Research, 134, 40-50.
20. Lv, X. C., Guo, W. L., Li, L., Yu, X. D., & Liu, B. (2019). Polysaccharide peptides from Ganoderma lucidum ameliorate lipid metabolic disorders and gut microbiota dysbiosis in high-fat diet-fed rats. Journal of Functional Foods, 57, 48-58.
21. Moszak, M., Szulińska, M., & Bogdański, P. (2020). You are what you eat—the relationship between diet, microbiota, and metabolic disorders—a review. Nutrients, 12(4), 1096.

22. Natividad, J. M., Agus, A., Planchais, J., Lamas, B., Jarry, A. C., Martin, R., ... & Sokol, H. (2018). Impaired aryl hydrocarbon receptor ligand production by the gut microbiota is a key factor in metabolic syndrome. Cell metabolism, 28(5), 737-749.

23. Rask Larsen, J., Dima, L., Correll, C. U., & Manu, P. (2018). The pharmacological management of metabolic syndrome. Expert review of clinical pharmacology, 11(4), 397-410.

24. Song, X., Zhong, L., Lyu, N., Liu, F., Li, B., Hao, Y., ... & Zhu, B. (2019). Inulin can alleviate metabolism disorders in ob/ob mice by partially restoring leptin-related pathways mediated by gut microbiota. Genomics, proteomics & bioinformatics, 17(1), 64-75.

25. Tilg, H., Zmora, N., Adolph, T. E., & Elinav, E. (2020). The intestinal microbiota fuelling metabolic inflammation. Nature Reviews Immunology, 20(1), 40-54.

26. Wang, P. X., Deng, X. R., Zhang, C. H., & Yuan, H. J. (2020). Gut microbiota and metabolic syndrome. Chinese medical journal, 133(07), 808-816.

27. Wang, Y., Li, N., Yang, J. J., Zhao, D. M., Chen, B., Zhang, G. Q., ... & Gai, Z. T. (2020). Probiotics and fructo-oligosaccharide intervention modulate the microbiota-gut brain axis to improve autism spectrum reducing also the hyper-serotonergic state and the dopamine metabolism disorder. Pharmacological research, 157, 104784.

28. Wang, Y., Yao, W., Li, B., Qian, S., Wei, B., Gong, S., ... & Wei, M. (2020). Nuciferine modulates the gut microbiota and prevents obesity in high-fat diet-fed rats. Experimental & molecular medicine, 52(12), 1959-1975.

29. Zeng, S. L., Li, S. Z., Xiao, P. T., Cai, Y. Y., Chu, C., Chen, B. Z., ... & Liu, E. H. (2020). Citrus polymethoxyflavones attenuate metabolic syndrome by regulating gut microbiome and amino acid metabolism. Science advances, 6(1), eaax6208.

30. Zheng, J., Cheng, G., Li, Q., Jiao, S., Feng, C., Zhao, X., ... & Liu, H. (2018). Chitin oligosaccharide modulates gut microbiota and attenuates high-fat-diet-induced metabolic syndrome in mice. Marine Drugs, 16(2), 66.